Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 2/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154955 | 0.75 | NOS1 (0.42) | NOS1MAPTKDRCYP3A4APEX1 | |
| SCHEMBL12480129 | 0.75 | MAPT (0.48) | NOS1MAPTDYRK1AKDRCYP3A4 | |
| SCHEMBL402053 | 0.75 | MAPT (0.48) | NOS1MAPTKDRCYP3A4APEX1 | |
| SCHEMBL2366705 | 0.75 | NOS1 (0.52) | NOS1MAPTDYRK1AKDRCYP3A4 | |
| SCHEMBL29935824 | 0.75 | NOS1 (0.39) | NOS1MAPTKDRCYP3A4APEX1 | |
| SCHEMBL18237595 | 0.72 | MAPT (0.42) | NOS1MAPTKDRCYP3A4APEX1 | |
| SCHEMBL9069902 | 0.71 | NOS1 (0.47) | NOS1MAPTDYRK1AKDRCYP3A4 | |
| SCHEMBL24655009 | 0.71 | MAPT (0.41) | NOS1MAPTKDRCYP3A4APEX1 | |
| SCHEMBL12726403 | 0.71 | MAPT (0.41) | NOS1MAPTKDRCYP3A4APEX1 | |
| SCHEMBL20156792 | 0.71 | MAPT (0.41) | NOS1MAPTKDRCYP3A4APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025101588-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-115768764-B | Parallel ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119156381-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024140851-A1 | TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF | 上海维申医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| EP-2867229-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014134341-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140249104-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| WO-2014002052-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014002058-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | NOS1 1108/4885MAPT 3172/4885DYRK1A 2883/4885 |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | NOS1 3221/4885MAPT 4777/4885DYRK1A 1987/4885 |
| US-20140249104-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | NOS1 2515/4885MAPT 523/4885DYRK1A 3906/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | NOS1 3084/4885MAPT 4024/4885DYRK1A 4409/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | NOS1 785/4885MAPT 432/4885DYRK1A 4675/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | NOS1 4625/4885MAPT 4614/4885DYRK1A 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.